Following the FDA’s approval of Leqembi (lecanemab), a monoclonal antibody that targets and helps destroy the hallmark beta-amyloid in Alzheimer's patients, the Centers for Medicare and Medicaid Services have proposed ending the once-per-lifetime limit on beta-amyloid PET scans.
Click here to read the full article.